Answers are grounded in this paper and cite their sources.
Theranostic biomarkers have emerged as a cornerstone of precision oncology, offering a unified platform that integrates disease detection, molecular characterization, and targeted therapy. In ovarian and endometrial cancers – two of the most molecularly diverse gynecologic malignancies – theranostic strategies have advanced from traditional serum markers to sophisticated receptor-based and nanotechnology-driven systems. Molecular targets such as BRCA /homologous recombination deficiency, folate receptor-α, HER2 , vascular endothelial growth factor, and mismatch repair/microsatellite instability enable real-time patient stratification and individualized treatment through imaging-guided and targeted interventions. The use of positron emission tomography/single-photon emission computed tomography tracers, magnetic resonance imaging-based contrast agents, and nanotheranostic platforms enhances diagnostic precision and therapeutic monitoring, whereas artificial intelligence-driven radiomics and multiomics integration promise to refine predictive modeling further. Although regulatory, ethical, and economic challenges persist, the convergence of molecular imaging, computational analytics, and personalized therapy heralds a transformative era for gynecologic oncology.
No takes yet. Share an insight, caveat, or question.
Gulhane et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: